Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

Imagine a world where breathing is a luxury and a cough marks the sound of an inner battle. Interstitial Lung Disease (ILD), a condition characterised by inflammation and fibrosis, is a major cause of ...

Active rash, interstitial lung disease and elevated neutrophil to lymphocyte ratio were independently associated with ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...

Liquidia Technologies ($LQDA) announced an update on their ongoing clinical study. Liquidia Technologies (LQDA) has announced plans for a Phase 3 ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Air pollution, asthma, COPD & lung care explained by a pulmonologist with simple tips to protect your lungs daily.